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Abstract (current: 212 words, MAX 300 words) 
It is now more than 50 years since the concepts of explanatory and pragmatic attitudes towards trials were 
first discussed by Schwartz and Lellouch in their influential 1967 paper. Since then there has been 
increasing focus on design aspects that may be consistent with more pragmatic attitudes within clinical 
trials, and a number of tools developed to assist investigators prospectively think about their trial design. 
Researchers have subsequently expressed interest in using these tools retrospectively to characterise trials 
as pragmatic or explanatory. We suggest that recent attempts to retrospectively dichotomise trials solely 
on the basis of quantitative scoring of trial design features are flawed. Instead, we argue that there is a 
need to consider both the intent and design when assessing the degree of pragmatism within a trial.  The 
practical implication of our suggestion for trial reporting is that investigators should explicitly state the 
intent of the trial through a clear articulation of the decision that they hope will be informed by the trial 
results. This should be coupled with a completed PRECIS-2 assessment (or similar) with an explanation 
of study design choices, in order to appropriately assess whether the study design is consistent with the 











Introduction and background 
It is now more than 50 years since the concepts of explanatory and pragmatic attitudes towards trials were 
first espoused by Schwartz and Lellouch (1967) in their influential paper on attitudes toward therapeutic 
trial design. These authors argued that approaches to study design, the question of interest, and the type of 
knowledge sought from the study are key elements to the “attitude” of a trial. As paraphrased by 
Zwarenstein and Treweek, pragmatic attitudes are those that seek to inform real world decisions regarding 
alternative treatments options while explanatory attitudes seek understand the mechanism of action of an 
intervention (Zwarenstein & Treweek, 2009) 
 
Interest in pragmatic randomized controlled trials (pragmatic RCTs) has increased substantially in recent 
years, and notably so since the turn of the century (Chalkidou et al., 2012; Patsopoulos, 2011). The 
increased interest is likely due to the need by decision makers at policy and clinical levels for more 
relevant and applicable research, and the needs of research funders to demonstrate the contribution of 
research tax dollars to health improvements. Further, there is concern that many trials have failed to 
predict the actual effectiveness of an intervention in later clinical practice, and diluted effects have been 
observed when interventions have been rolled out to a broader clinical population. In part, this has been 
attributed to the disconnect between their intent and their design (Ford & Norrie, 2016). Others have 
noted that explanatory RCTs often exclude individuals who would likely receive a study intervention in 
practice, leading to a lack of good quality evidence to inform many treatment decisions for these 
populations (Roland & Torgerson, 1998). While some commentators believe that particular design 
features, such as blinding or placebo controls, may be sufficient to rule out a trial as pragmatic, others 
have argued that such features should not be defining characteristics of a pragmatic trial (Dal-Ré, 2019; 
Dal-Ré et al., 2018; Sedgwick, 2014; Kevin E. Thorpe et al., 2010; K. E. Thorpe et al., 2009; Zwarenstein 
et al., 2008). As such, whether certain features would exclude a trial from being pragmatic remains an 




As interest in pragmatic RCTs has increased, a number of tools (Koppenaal et al., 2011; Loudon et al., 
2015; K. E. Thorpe et al., 2009) have been developed to assist investigators evaluate the appropriateness 
of design decisions when thinking about their trial design. Notably, these tools have increasingly involved 
quantitative elements that allow trials to be scored across domains. While these tools have been developed 
for prospective use, researchers have also expressed interest in retrospectively applying these tools to trial 
reports in order to evaluate and classify trials as pragmatic or not (Sajobi et al., 2018; Yoong et al., 2014). 
Thus, there has been increasing focus on the quantification of design features and attempts to categorise 
trials based purely on these design features.  
 
In the present analysis we highlight, and critique, two separate but related aspects of this focus. First, we 
argue that it is imperative that the trial attitude (or what we shall call the trial intent) is integrated with 
consideration of the design features. This contention is based on our belief that the design of a trial should 
flow from its intent (and the decision to which the results of the trial are intended to be applicable) and 
thus a focus purely on retrospective quantitative evaluation, and classification based on this score, ignores 
the trial intent and potential applicability of the findings. Second, we note that there remain a number of 
conceptual and practical impediments to categorisation of trials based on retrospective scoring of trial 
design characteristics, not least the lack of consensus regarding the placement of thresholds (if at all), 
weighting of different trial characteristics, and reported variation in the scoring of individual 
characteristics.  
 
The structure of the manuscript is as follows: We first review tools developed for investigators to evaluate 
trials in relation to their intent. We then critique how use of these tools has evolved. We conclude by 
arguing that trial evaluations cannot be judged solely on an abstract retrospective review of design 
features but requires both an understanding of the intent of the trial and how the design relates to this 




Specifying the domains of pragmatic trials: the development of frameworks and tools for 
prospective assessment 
 
Since Schwartz and Lellouch (Schwartz & Lellouch, 1967) first promoted the idea of pragmatic and 
explanatory attitudes toward trials, there has been increasing attempts to formalise and quantify trial 
design features that are consistent with a pragmatic intent (see Supplementary Material S1 for examples 
and Loudon et al., 2013a; Pawson, 2019a for discussions of frameworks and dimensions within these). 
These tools include, the PRagmatic-Explanatory Continuum Indicator Summary (PRECIS) which 
included 10 domains with a visual scale to represent where the trial fell on each domain (K. E. Thorpe et 
al., 2009). PRECIS was later revised to PRECIS-2 (Loudon et al., 2015; Loudon et al., 2013b)  which 
further revised the domains but also incorporated a quantification of the degree to which the design 
reflected the underlying pragmatic orientation of the trial (using a 5-point Likert-style scale). This 
addition of a score within each domain was consistent with work that had been undertaken in the 
intervening period and which had sought to apply scoring mechanisms to the original PRECIS domains. 
The introduction of quantitative assessment was due to noted variation in the application of the original 
PRECIS tool and was thus sought to standardise the assessment of trial design features by introducing a 
common scale. 
 
As these tools have evolved, so has their use.  In contrast to the initial development of tools for 
prospective use by trial investigators to evaluate their own trial, tools such as the PRECIS-RT tool 
(Koppenaal et al., 2011) have been developed and applied in retrospective analyses of trial reports. This 
has represented a significant change in orientation from prospective assistance for trial investigators to 
retrospective evaluation by researchers not involved in the original trial. Multiple studies have now 
sought to apply existing tools retrospectively in order to classify trials as either pragmatic or explanatory 
(Aves et al., 2017; Devos et al., 2019; Palese et al., 2014; Steel et al., 2017; Yoong et al., 2014). For 
example, Yoong et al (2014) explored the intervention effect size according to the categorization of a 
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trial, while Aves et al sought to explore whether designation of the trial may be informative with respect 
to explaining inconsistent trial results (Aves et al., 2017). As such, despite repeated statements that RCTs 
sit along an explanatory-pragmatic spectrum (Gartlehner et al., 2006; Neta & Johnson, 2018; Oxman et 
al., 2009; K. E. Thorpe et al., 2009), or indeed a multi-axial continuum, there are now attempts to 
retrospectively evaluate and score trials and apply thresholds by which to dichotomise trials as pragmatic 
or not.   
 
 
Both of these moves (retrospective assessment of the degree of pragmatism in design features, and overall 
classification of trial design as pragmatic or explanatory) reflect a change from the original orientation 
which was to assist trial investigators understand the degree to which their trial design was consistent 
with the intention of the trial.  
 
Why does this matter? 
The importance of the co-consideration of intent and design is underscored by the failure of many trials to 
predict the actual effectiveness of an intervention in later clinical practice (Zwarenstein & Treweek, 
2009), in part due to the disconnect between their intent and their design. The integration of intent is 
important because a focus solely of metrics (and subsequent dichotomous categories of pragmatic or 
explanatory trials based on this) abstracts design from intent and whether a design is ‘fit for purpose’. 
Indeed, the increasing focus on metrics illustrates the partial adoption of tools such as PRECIS-2; 
attention has been focused on the production of the scores, or in the case of PRECIS-2, the ‘wheel’, to the 
detriment of other aspects such as consideration of the PRECIS-2 table which requires investigators to 
provide a rationale for the design choices within each PRECIS-2 domain (https://www.precis-
2.org/Help/Documentation/ToolkitDownload). While the PRECIS-2 domain scores can provide a useful, 
shorthand assessment of a trial’s pragmatism along various dimensions, the explicit rationales sought by 
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the PRECIS-2 table offer a far more informative picture of how, and in what respects, the trial 
investigators considered their trial to be pragmatic. 
 
While one may argue that all trials in which the intent is to generate evidence applicable to a clinical or 
policy decision should be required to score highly on tools such as PRECIS-2, it pays no consideration to 
legal requirements, questions of feasibility, nor whether particular elements of design may be more 
appropriately designed to be more explanatory in order to best provide evidence relevant to the clinical or 
health policy question at hand.   
 
In order to more completely understand and evaluate the design features of a trial, both as originally 
designed and subsequently operationalised, the design information must be placed into context. We 
therefore assert that the PRECIS-2 table, or similar demonstration of design rationale, is integral to 
evaluating whether the study design is consistent with the intent of the trial. 
 
Integrating intent 
It should be remembered that pragmatic RCTs are intended to have their results be applicable to clinical 
or health policy decisions (Maclure, 2009; Zwarenstein & Treweek, 2009). While tools such as PRECIS 
were developed to assist investigators to evaluate their trial design with respect to the decision that the 
trial intended to inform, it does not prescribe a specific study design or set of design features. A focus on 
the retrospective quantitative evaluation and classification based on this score completely ignores whether 
the trial is consistent with the stated intent, which may reflect more pragmatic or explanatory attitudes. 
Moreover, the applicability of trial results will depend on the specific context of the trial and 
transferability of the trial results rather than an abstract score of the design features (Pawson, 2019b). 
Rather, we reiterate that the research design should be predicated on the research question which derives 




To further illustrate our position, Table 1 provides examples of studies that clearly articulate the intention 
of the trial. 
 
[TABLE 1 ABOUT HERE] 
 
Conceptual and practical difficulties in retrospectively applying thresholds based on PRECIS-2 
In addition to the above noted need to consider the intent of the trial, we see several conceptual and 
practical difficulties in the retrospective evaluation and classification of RCTs, namely: inconsistency and 
lack of consensus regarding thresholds by which to establish what constitutes a pragmatic trial, epistemic 
uncertainty regarding the relevant contribution of specific domains to the overall evaluation of the trial, 
and; practical limitations due to noted variation in assessment and incompleteness of reporting. 
 
[TABLE 2 ABOUT HERE] 
 
First, proposed thresholds used to categorise trials have varied, with no consensus about the thresholds to 
use (Aves et al., 2017; Devos et al., 2019; Sajobi et al., 2018; Steel et al., 2017; Yoong et al., 2014). 
Yoong and colleagues (Yoong et al., 2014), created an ordered set of categories (explanatory, a 
combination of pragmatic and explanatory, or pragmatic) with thresholds based on the average of scores 
across the nine PRECIS-2 domains. Sajobi et al (2018) used the same scoring mechanism as Yoong and 
colleagues (average score across PRECIS-2 domains). Rather than an ordered set of categories they 
applied a threshold to dichotomise the classification (see Table 2). In each case, the proposed thresholds 
lack clear rationales or justifications for their choice, leading to incompatibility between studies. Further, 
there is epistemic uncertainty as to the relevant weight that should be ascribed to individual design 
features, that is, each domain of PRECIS-2 (Dekkers et al., 2017; Pawson, 2019a). This question of 




“Eligibility criteria are likely to always be crucial, but the flexibility of the comparison 
intervention, for example, may sometimes be less important. We do not have a clear answer 
to this problem, especially because the best weighting of the domains could depend on the 
situation.” (Koppenaal et al., 2011) 
 
This again emphasises that the importance of design features should be evaluated with respect to the 
stated intent of the trial; the weighting may be dependent on the situation, that is the intent of the trial or 
the decisions to be informed. For example, criteria such as participant eligibility will likely be relevant to 
all studies, yet the flexibility of the comparison intervention, or organisation and structure (if part of the 
intervention) may vary in importance (Dal-Ré et al., 2018; Koppenaal et al., 2011). Yet in most studies 
that seek to apply quantitative scores to determine whether a trial is pragmatic or not, the relative 
contribution of each domain to the overall score is not discussed (Luoma et al., 2017; Sanchez et al., 
2013; Sepehrvand et al., 2019; Witt et al., 2012). We believe that the relative contributions that individual 
domains should contribute toward the overall assessment of the trial – including the extent to which the 
domain-related design features appropriately reflect the intent of the trial – requires further conceptual, 
and potentially empirical, consideration.  
 
Second, and on a more practical note, the ability to evaluate and classify trials retrospectively is highly 
varied. As Pawson notes, a key issue is whether different observers, from different backgrounds and 
interested in different conditions, will view the dimensions in the same manner and be equally calibrated 
so as to come to the same conclusion regarding the pragmatism of a trial (Pawson, 2019a). In the 
development of PRECIS-2, Loudon et al. (Loudon et al., 2017) conducted an inter-rater reliability study 
regarding the retrospective application of the PRECIS-2 tool. They noted that seven of nine domains had 
an intraclass correlation coefficient (ICC) over 0.65 but that two (flexibility-adherence, and recruitment) 
had lower ICCs and wide confidence intervals (Loudon et al., 2017). This variation in domain scores has 
been found across empirical studies of retrospective evaluation (Gaglio et al., 2014; Glasgow et al., 2012; 
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Loudon et al., 2017). Moreover, Loudon et al., (Loudon et al., 2017) found that discriminant validity of 
the PRECIS-2 scores was modest, further supporting the argument to say that such a tool is of limited use 
with respect to retrospectively evaluating trials as pragmatic or explanatory. Again Pawson, as we concur, 
states that a challenge here is that such measurement itself is indirect (Pawson, 2019a). A score on a tool 
such as PRECIS-2 is not an intrinsic metric — rather, each domain score can be thought of as an indicator 
of an underlying latent construct requiring judgement or interpretation which may differ between 
individuals. 
 
Finally, the scoring of trials retrospectively is further hampered by missing data in reports, a topic that has 
been repeatedly highlighted by authors attempting to retrospectively apply scoring mechanisms (Aves et 
al., 2017; Koppenaal et al., 2011; Loudon et al., 2017; Yoong et al., 2014). The variation in the 
retrospective scoring of trials, together with noted prevalence of missing data, illustrates that quantifying 
the degree of pragmatism within a trial based purely on reported design features is both variable and 
subject to how well the trial is reported.  
 
It seems premature, therefore, to advocate for the use of retrospective evaluation and categorisation of 
trials as pragmatic or not given the noted variation in assessment, conceptual uncertainty regarding 
weighting of domains, and the absence of consensus regarding where thresholds should be placed (if at 
all).  
 
Practical implications of our proposal 
We propose that trial investigators should explicitly state their intent through explicit discussion of the 
decision(s) to which the trial is intended to provide applicable data. This should be done prospectively as 
they develop the design of the trial. The study design should then flow from this intent and thus the 
design of a trial should be judged in conjunction with the stated intent. Further, we suggest that in 
addition to a formal statement regarding the decision that the trial results should be applicable to, 
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investigators should indicate the relative importance of design features to the decision at hand. For 
example, in the context of pragmatic RCTs comparing vaccine dosing schedules or storage (Juan-Giner et 
al., 2014; Neuzil et al., 2011), the primary outcome may be immunogenicity based on antibody levels. 
This may, by examination of the PRECIS-2 guidance, be scored as a very explanatory outcome. However, 
given the prominence of this outcome within policy decision-making, this outcome choice may be 
appropriate and as such a lower PRECIS-2 score may carry less weight with respect to the overall 
assessment of the trial. Similarly, the importance of pragmatism in the analytic approach (for example the 
use of intention to treat analysis and per protocol analysis) may vary depending on the question being 
addressed (Murray et al., 2018; Murray et al., 2019). In Supplementary Material S1 we propose an 
enhanced version of the existing PRECIS-2 toolkit table which incorporates these suggestions.  
 
Despite our suggestion, we acknowledge that there is an implementation gap between the completion of a 
trial and the impact, if any, of that trial on clinical practice or policy. This does not, we believe, change 
the need for the reports of pragmatic trials to be accessible and understandable. We believe our proposal 
would provide the contextual information to evaluate the appropriateness of the study design in relation to 
the decision that the trial results were intended to be applicable. This is not a new requirement and is 
explicitly included within the CONSORT extension for pragmatic trials which states: 
 
“Users of pragmatic trial reports seek to solve a health or health service problem in a 
particular setting. The problem at which the intervention is targeted should thus be described. 
This enables readers to understand whether the problem confronting them is similar to the 
one described in the trial report, and thus whether the study is relevant to them. Ideally, the 
report should state that the trial is pragmatic in attitude (and why) and explain the purpose 
of the trial in relationship to the decisions that it is intended to inform and in which settings.” 




We suggest that this should not be an aspirational ideal but a necessary component, and that both the trial 
protocol and original trial report should explicitly detail how pragmatic design features reflect the needs 
of the trial in relation to the decision that the trial is intended to inform. We suggest that a completed 
version of our enhanced PRECIS-2 table could be included as supplementary material for trials with a 
pragmatic intent. Further, recent analysis of self-identified pragmatic trials supported by the US National 
Institutes of Health illustrates how initial trial designs may be required to adapt when a trial begins 
implementation.(Johnson et al., 2016), suggesting that clear reporting is needed at both the concept or 
protocol stage and upon trial completion. Understanding how the implemented trial is consistent or 
divergent from the initial intent will again enhance understand of the degree to which the findings of the 
implemented trial are relevant to the decision that the trial results were intended to inform. In short, it 
allows for the explicit examination of whether the final trial design was in-keeping with the intent and 
thus ‘fit for purpose.’ 
 
We thus concur with Dal-Ré and colleagues (Dal-Ré et al., 2018) that transparent and complete reporting 
of trials is essential to their proper evaluation, and that adherence to the proposals within the CONSORT 
extension for pragmatic trials should be promoted (Zwarenstein et al., 2008). This will not just benefit 
researchers and knowledge users with respect to making assessments regarding the intent of the trial and 
the degree to which this reflects a pragmatic orientation, but it will also facilitate an understanding of 
appropriateness of the consequent trial design.  
 
Conclusion 
In conclusion, we argue against the quantitative evaluation and categorisation of trials as pragmatic or 
explanatory solely on the basis of design elements, such as those provided in PRECIS-2. Moreover, we 
suggest that it is the responsibility of investigators to state the relative emphasis that should be placed on 
specific design domains. However, there remains a need for conceptual and empirical study of the 
relevant contributions that different domains make toward the overall degree of pragmatism within a trial, 
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and under what circumstances the weights of the domains may differ. We contend that existing examples 
of dichotomisation are conceptually problematic but also raise practical concerns, and a more appropriate 
response requires one to evaluate the overall trial design (as articulated through a complete PRECIS-2 
assessment or similar) in the context of the decision the trial was intended to inform. We believe that a 
focus on the integration of intent and design is more in keeping with the original work with the original 
work by Schwartz and Lellouch. When coupled with more complete and transparent reporting this will 
create less arbitrary classification of trials.  
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Table 1: Published trials with clear statement of trial intent 
 
Trial name and reference Text demonstrating intent 
Cox, et al., (2014). "Impact of Xpert MTB/RIF for TB 
diagnosis in a primary care clinic with high TB and 
HIV prevalence in South Africa: a pragmatic 
randomised trial." PLoS Med 11(11): e1001760. 
“While significant data exist on the specificity and sensitivity of Xpert testing [6], there are limited 
data available on the impact of implementing Xpert on health outcomes in routine programmatic 
settings [7,8]. As a result, there remains controversy as to how Xpert should be implemented in 
different health systems and who should be tested. We aimed to assess the impact of using Xpert for 
TB diagnosis on yield of TB cases and the timing of TB treatment initiation in a large primary health 
care clinic, through a pragmatic randomised controlled trial” 
Witt, et al., (2015). "Effectiveness of an additional 
individualized multi-component complementary 
medicine treatment on health-related quality of life in 
breast cancer patients: a pragmatic randomized trial." 
Breast Cancer Res Treat 149(2): 449-460. 
“ […] In January 2010, the regional public health system in South Tyrol (Italy) established a service 
for CM at the Merano Hospital planned to run for 2 years, and aiming to improve quality of life in 
cancer patients and patients with chronic conditions. The present study was initiated by the regional 
public health system to inform the decision whether or not the service should be maintained after 
December 2012. Therefore, the primary aim of this study was to evaluate the effectiveness of an 
additional, individualized, multi-component CM treatment offered at the Merano Hospital compared 
to usual care only on health-related quality of life in patients with breast cancer.” 
Anderson, et al., (2018). "Randomised controlled trial 
to assess the impact of a lifestyle intervention 
(ActWELL) in women invited to NHS breast 
screening." BMJ Open 8(11): e024136. 
“The current study is designed to assess the effectiveness of a community-based, personalised, 
minimal contact weight management programme in women with a BMI >25 kg/m2 attending routine 
breast cancer screening clinics. The intervention programme is a collaboration between the charity 
Breast Cancer Now (BCN), NHSSBSP, local authority leisure centres and academic partners. This 
work is the first time that a cancer charity has offered volunteer capacity for cancer prevention action 
on weight management and offers significant potential to address gaps in public health efforts. The 
design is pragmatic to increase the relevance of the findings to policymakers, women eligible for 
breast screening and health professionals (see online supplementary appendix 1).” p2-3 
Than, et al., (2016). "Effectiveness of EDACS Versus 
ADAPT Accelerated Diagnostic Pathways for Chest 
Pain: A Pragmatic Randomized Controlled Trial 
Embedded Within Practice." Ann Emerg Med 68(1): 
93-102 e101. 
“Clinicians do not always adhere to clinical pathways or guidelines as expected, and it is important to 
determine whether the EDACS-ADP would work within a clinical pathway implemented into daily 
hospital care when the attending clinician has final decision-making authority. We therefore designed 
a trial to test for the existence and size of any beneficial effect of using the EDACS-ADP in routine 
clinical care. We tested the null hypothesis that there was no difference in using the EDACS-ADP to 
classify patients to low-risk category and early discharge from the ED than using the modified 
ADAPT-ADP.” 
Butler et al., (2020). "Oseltamivir plus usual care 
versus usual care for influenza-like illness in primary 
care: an open-label, pragmatic, randomised controlled 
trial." The Lancet 395(10217): 42-52. 
“We deliberately chose to do an open-label trial in the context of everyday practice, because effect 
sizes identified by placebo-controlled, efficacy studies with tight inclusion criteria might not be 
reproduced in routine care. We also wished to estimate time to patient reported recovery from the 
addition of an antiviral agent to usual care rather than benefit from oseltamivir treatment compared 
with placebo […] This pragmatic, open trial design makes our findings likely to reflect real world 
effects in primary care, because knowledge of what medication one is taking could affect subsequent 
help seeking and health behaviour and use of symptomatic medications. uncomplicated influenza 
found a similar effect to our study overall and observed reductions in the duration of symptoms and 




TABLE 2: Studies applying thresholds to the PRECIS-2 domain scores 
Author Rationale for categorisations Scoring mechanism Rationale for 
threshold level(s) 
Yoong et al., 2014 “Given that findings from pragmatic trials are more likely 
to closely approximate the public health impacts caused by 
an intervention if investments were made to introduce it 
into the community, examining intervention outcomes 
based on trial design is likely to provide more useful 
information for assessing the transferability of public 
health initiatives 
Studies were classified as Pragmatic (average score on 
PRECIS-2 >2.2); Combination pragmatic/explanatory 
(average score >1.7 - ≤ 2.2 ), or Explanatory (average 
score ≤ 1.7 ).  
Not given 
Aves et al 2017 “If heterogeneity is substantial, due to the degree of 
pragmatism, it might not be appropriate to pool data from 
pragmatic and explanatory trials. The use of the PRECIS-2 
tool could provide important information for authors of 
systematic reviews with regards to pooling data from 
primary RCTs based on the degree of pragmatism.” 
Proposed to use the same cut offs as Yoong et al., (2014) Not given 
Steel et al 2017 Not given “Articles reporting comparative effectiveness research 
were scored using the PRagmatic-Explanatory 
Continuum Indicator Summary-2 (PRECIS-2) tool 
(Loudon et al., 2015) and independently categorised as 
employing either an explanatory or observational design 
by two investigators” 
Not given 
Sajobi et al. 2018 “Although modern meta-analytic methods such as mixture 
metaregression and robust meta-analytic methods have 
been developed to pool evidence from heterogeneous 
populations [26–28], there is limited application of these 
methods and incorporation of PRECIS ratings in 
synthesizing evidence from explanatory and pragmatic 
trials.” 
Explanatory if PRECIS-2 average score <3.0, Pragmatic 
if ≥ 3.0.  
Not given 
Dal-Ré et al., 2018 “Trials with features that defy pragmatism have been 
labeled as pragmatic in all types of journal, including 
major general medical journals such as BMJ and Annals of 
Internal Medicine. These cases exemplify how the use of 
the term “pragmatic” needs better standardization.” 
Extremely pragmatic: of all 9 domains score ≥4  
Pragmatic: scores ≥4 in 4–5 domains, provided the 
scores of the remaining domains are 3 
Exception: highly pragmatic trials where the intervention 
is how care is organized (and hence the ‘organisation’ 
domain score will be in the explanatory extreme [12]), 
could be labeled as pragmatic since this is just an explicit 





Supplementary Material S1. Chronological listing (by year of publication) of selected assessment frameworks and tools developed to 
capture the domains upon which trials may be more or less pragmatic 
Author Year Tool Purpose/Rationale Details Scoring 
Gartlehner et 
al.(Gartlehner 
et al., 2006) 
2006 Not formally 
named, but 
described as a 




“Distinguishing between efficacy and 
effectiveness contributes an important 
aspect to analyzing any body of 
clinical evidence […] we propose and 
test seven hallmarks of study design 
to create a tool that can help 
researchers and those producing 
systematic reviews, as well as 
clinicians who are interested in the 
generalizability of study results, to 
distinguish more readily and more 
consistently between efficacy and 
effectiveness studies.” 
7 items: Populations in primary care, 
Less stringent eligibility criteria, 
Health outcomes, Long study 
duration with clinically relevant 
treatment modalities, Assessment of 
adverse events, Adequate sample size 
to assess a minimally important 
difference from a patient perspective, 
Intention To Treat (ITT) analysis 
Items rated as binary Yes/No 
Thorpe, et 
al(K. E. 








“The primary aim of this tool is to 
help trialists to assess the degree to 
which design decisions align with the 
trial’s stated purpose (decision-
making vs. explanation). Our tool 
differs therefore from that of 
Gartlehner et al. in that it is intended 
to inform trial design rather than 
provide a method of classifying trials 
for the purpose of systematic 
reviews.” 
10 domains: Participant eligibility 
criteria, Experimental intervention 
flexibility, Experimental intervention 
practitioner expertise, Comparison 
intervention, Comparison 
intervention practitioner expertise, 
Follow up intensity, Primary trial 
outcome, Participant adherence to the 
“prescribed” intervention, 
Practitioner adherence to study 
protocol, Analysis of primary 
outcome. 
Visual ‘hub and spoke’ 
diagram for the domains, but 
no formal scoring. 
Tosh G, et 
al.(Tosh et 
al., 2011) 
2011 PRAGMASCOPE “The main goal of this study is to 
adapt the instrument described by 
Thorpe et al (PRECIS) to assist 
researchers in making those 
judgments in the protocol stage of 
RCTs in mental health (the 
Pragmascope tool).” 
Includes the 10 PRECIS Domains: 
Participant eligibility criteria, 
Experimental intervention flexibility, 
Experimental intervention 
practitioner expertise, Comparison 
intervention, Comparison 
intervention practitioner expertise, 
Follow up intensity, Primary trial 
outcome, Participant adherence to the 
“prescribed” intervention, 
Practitioner adherence to study 
Each domain is scored from1 
(most explanatory) to 5 (most 
pragmatic). Scores summed 
and broad grouping applied: 
“scores was of 0 to 30 for an 
explanatory study investigating 
whether the experimental 
intervention will work in ideal 
circumstances and a total score 
>35 for a more pragmatic 
study focusing mostly on 
whether, in routine practice, an 
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protocol, Analysis of primary 
outcome. 
 
intervention has a meaningful 
effect. A total score between 
31 and 39 were interpreted as 
an interim where trial design 
balances pragmatic and 
explanatory domains.”  Later 








“[…] because the PRECIS tool 
results in a figure for each trial, it is 
not possible to assess a review. 
Therefore, in this article we propose a 
modification of the PRECIS tool so 
that it can be used to judge a 
systematic review. This serves two 
purposes. First, calculating a numeric 
score makes it possible to score a 
systematic review and place it on the 
pragmatic-explanatory continuum. 
Second, the separate trials in the 
review can be scored. This may help 
in selecting the trial that is the most 
pragmatic, assuming that the results 
of that trial are the most relevant for 
policy makers.” 
Applied the PRECIS domains within 
two systematic reviews. For each 
review. Each RCT within the 
systematic review is scored on the 10 
domains; an average score per RCT 
is calculated; a domain average 
across the review calculated, and; a 
total average for the systematic 
review can be calculated. 
Each domain is scored 1 
(extreme explanatory study) to 
5 (extreme pragmatic study). 
Scores also transformed to 
percentages where 0% 
represents an extremely 
explanatory study and 100% 
represents an extremely 
pragmatic study.  
Loudon et 
al..(Loudon 
et al., 2015) 
2015 PRECIS-2 “While acknowledging the usefulness 
of PRECIS, these latter authors have 
identified weaknesses, including 
unclear face validity and inter-rater 
reliability, the lack of a scoring 
system, redundancy in some PRECIS 
domains, and the need for more 
guidance on how to use the tool.” 
Nine domains: Eligibility, 
Recruitment, Setting, Organisation, 
Flexibility (delivery), Flexibility 
(adherence), Follow-up, Primary 
outcome, Primary analysis. 
Each domain can be scored 






and Bossie et 
al.,(Bossie et 
al., 2016)  
2016 ASPECT-R “Janssen Pharmaceuticals, Inc. has 
adapted ideas from these instruments 
to build a still more versatile 
instrument. The number of domains 
has been reduced to six that are 
specifically explanatory-pragmatic 
spectrum. Domains identified as 
Developed by Janssen 
Pharmaceuticals, Inc (2014). Includes 
6 domains; Participant eligibility 
criteria, Intervention flexibility, 
Medical practice setting/practitioner 
expertise, Follow up intensity and 
Each item score from 0 
(extremely explanatory) to 6 
(extremely pragmatic).  
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redundant and domains focused on 
measures of study quality have been 
eliminated.”(Alphs & Bossie, 2016) 
 
“As opposed to the 10-domains of 
the PRECIS and Pragmascope 
instruments, the ASPECT-R tool 
assesses six study design domains, 
with these domains specifically 
related to the explanatory: pragmatic 
spectrum. The four domains excluded 
when developing the ASPECT-R tool 
were those considered to be 
redundant or more focused on 
measures of study quality […] The 
ASPECT-R tool is 
considered useful in the study design 
stage as well as to assess the 
explanatory versus pragmatic nature 
of published trials.”(Bossie et al., 
2016) 




et al., 2017) 
2017 Rating of 





“PRECIS and PRECIS-2 were 
developed to inform choices during 
the trial design phase, rather than to 
assess the characteristics of trial 
evidence retrospectively from the 
publication of the trial. They assume 
detailed familiarity with available 
design options at the time that the 
trial is being designed, and this 
information may not be available in 
the report of a completed trial. In 
addition, PRECIS-2 assesses nine 
trial domains which may limit the 
practicality for use on the often 
substantial number of trials included 
in a systematic review.” 
 Four domains: participants’ 
characteristics, trial setting, 
flexibility of intervention(s), and 
clinical relevance of experimental 
and comparison intervention(s). 
Each domain is rated on a five-
point scale from a strong 
emphasis on efficacy to a 






Supplementary Material S2: Proposed Enhanced PRECIS-2 table 
 
Step 1: Why are you doing your trial? 
The first step is to be clear why you are doing your trial. Are you: 
1. Aiming to take an explanatory approach to answer the question ‘Can this intervention work under ideal conditions?’  
2. Aiming to take a pragmatic approach and answer the question ‘Does this intervention work under usual conditions?’ 
 
If the latter then specify the decision to be informed, noting the particular stakeholder perspective taken. Is this a clinical decision – for example, 
which treatment should be selected? –  or is it perhaps a health policy decision about what interventions to provide or fund?  
 
Step 2: Consider your trial design choices for each of the nine PRECIS-2 domains. Using the table score each domain on a score of 1 to 5 where 
these correspond to:  
 
1. Very explanatory  
2. Rather explanatory  
3. Equally pragmatic/explanatory  
4. Rather pragmatic  
5. Very pragmatic 
 
Step 3: For each domain explain how the design chosen, and the degree of pragmatism, relates to the decision to which the trial results should be 
applied. As part of this investigators should discuss each domain in terms of its relative importance to the decision that is to be informed. For 
example, a physiological outcome may be chosen (and may be scored as “1.Very explanatory”), but this may be the main clinical outcome used in 
practice and so may be an appropriate outcome and relevant to the decision being informed. Similarly, the importance of pragmatism in the 
analytic approach (for example the use of intention to treat analysis and per protocol analysis) may vary depending on the question being 
addressed. 
 
The table should be used in conjunction with the PRECIS-2 “wheel” or instead of the wheel to give rationale for scores. You can use this to assist 





Description of decision that the 
trial is intended to inform 
 
 
Domain Score Rationale and description of the design choice in relation to the decision that the trial is intended to inform. Each 
domain should also be discussed in terms of its relative importance to the decision that is to be informed 
1 Eligibility Criteria 
  

















7 Follow up 
  
8 Primary outcome 
  
9 Primary analysis 
  




The 9 PRECIS-2 domains are:  
Eligibility –to what extent are the participants in the trial similar to those who would receive this intervention if it was part of usual care? For example, score 
5 for very pragmatic criteria essentially identical to those in usual care; score 1 for a very explanatory approach with lots of exclusions (e.g. those who don’t 
comply, respond to treatment, or are not at high risk for primary outcome, are children or elderly), or uses many selection tests not used in usual care.  
 
Recruitment - how much extra effort is made to recruit participants over and above what that would be used in the usual care setting to engage with 
patients? For example, score 5 for very pragmatic recruitment through usual appointments or clinic; score 1 for a very explanatory approach with targeted 
invitation letters, advertising in newspapers, radio plus incentives and other routes that would not be used in usual care.  
 
Setting – how different is the setting of the trial and the usual care setting? For example, score 5 for a very pragmatic choice using identical settings to usual 
care; score 1, for a very explanatory approach with only a single centre, or only specialised trial or academic centres.  
 
Organisation – how different are the resources, provider expertise and the organisation of care delivery in the intervention arm of the trial and those 
available in usual care? For example, score 5 for a very pragmatic choice that uses identical organisation to usual care; score 1 for a very explanatory 
approach if the trial increases staff levels, gives additional training, require more than usual experience or certification and increase resources.  
 
Flexibility (delivery) – how different is the flexibility in how the intervention is delivered and the flexibility likely in usual care? For example, score 5 for a 
very pragmatic choice with identical flexibility to usual care; score 1 for a very explanatory approach if there is a strict protocol, monitoring and measures to 
improve compliance, with specific advice on allowed cointerventions and complications.  
 
Flexibility (adherence) - how different is the flexibility in how participants must adhere to the intervention and the flexibility likely in usual care? For 
example, score 5 for a very pragmatic choice involving no more than usual encouragement to adhere to the intervention; score 1 for a very explanatory 
approach that involves exclusion based on adherence, and measures to improve adherence if found wanting. In some trials eg surgical trials where patients 
are being operated on or Intensive Care Unit trials where patients are being given IV drug therapy, this domain is not applicable as there is no compliance 
issue after consent has been given, so this score should be left blank.  
 
Follow-up - how different is the intensity of measurement and follow-up of participants in the trial and the likely follow-up in usual care? For example, 
score 5 for a very pragmatic approach with no more than usual follow up; score 1 for a very explanatory approach with more frequent, longer visits, 
unscheduled visits triggered by primary outcome event or intervening event, and more extensive data collection.  
 
Primary outcome – to what extent is the trial's primary outcome relevant to participants? For example, score 5 for a very pragmatic choice where the 
outcome is of obvious importance to participants; score 1 for a very explanatory approach using a surrogate, physiological outcome, central adjudication or 
use assessment expertise that is not available in usual care, or the outcome is measured at an earlier time than in usual care.  
 
Primary analysis – to what extent are all data included in the analysis of the primary outcome? For example, score 5 for a very pragmatic approach using 
intention to treat with all available data; score 1 for a very explanatory analysis that excludes ineligible post-randomisation participants, includes only 
completers or those following the treatment protocol. 
https://www.precis-2.org/Help/Documentation/ToolkitDownload 
